Can Fite Biopharma Ltd (TA:CANF) — Stock Price
Can Fite Biopharma Ltd (TA:CANF) is currently trading at ILA520.00 ILA, down 1.83% today. Over the past 52 weeks, shares have ranged between ILA1.00 and ILA1500.00. This page tracks Can Fite Biopharma Ltd's live share price on the TA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see CANF company net worth.
Can Fite Biopharma Ltd (CANF) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Can Fite Biopharma Ltd's daily closing share price and trading volume on the TA exchange over the past year, giving a clear view of recent price momentum and liquidity.
Can Fite Biopharma Ltd Income Statement — Revenue, Profit & Earnings by Year
Can Fite Biopharma Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ILA438.40K | ILA674.00K | ILA743.00K | ILA810.00K | ILA853.00K |
| Cost of Revenue | ILA25.98K | — | — | — | — |
| Gross Profit | ILA412.42K | ILA674.00K | ILA743.00K | ILA810.00K | ILA853.00K |
| Research & Development | ILA7.24 Million | ILA5.76 Million | ILA5.98 Million | ILA7.76 Million | ILA9.85 Million |
| SG&A | ILA3.66 Million | ILA3.05 Million | ILA2.96 Million | ILA3.14 Million | ILA3.85 Million |
| Total Operating Expenses | ILA11.18 Million | ILA8.80 Million | ILA8.94 Million | ILA10.91 Million | ILA13.70 Million |
| Operating Income | ILA-10.77 Million | ILA-8.13 Million | ILA-8.20 Million | ILA-10.10 Million | ILA-12.84 Million |
| EBITDA | ILA-10.74 Million | ILA-8.12 Million | ILA-8.18 Million | ILA-10.08 Million | ILA-12.83 Million |
| EBIT | ILA-10.77 Million | ILA-8.13 Million | ILA-8.20 Million | ILA-10.10 Million | ILA-12.84 Million |
| Interest Expense | ILA15.15K | ILA14.00K | ILA14.00K | ILA77.00K | ILA18.00K |
| Income Before Tax | ILA-10.64 Million | ILA-7.88 Million | ILA-7.63 Million | ILA-10.17 Million | ILA-12.62 Million |
| Income Tax Expense | — | — | — | ILA360.00K | ILA-20.00K |
| Net Income | ILA-10.64 Million | ILA-7.88 Million | ILA-7.63 Million | ILA-10.17 Million | ILA-12.60 Million |
Can Fite Biopharma Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Can Fite Biopharma Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ILA9.52 Million | ILA9.12 Million | ILA9.99 Million | ILA9.28 Million | ILA20.25 Million |
| Total Current Assets | ILA9.44 Million | ILA8.98 Million | ILA9.91 Million | ILA9.16 Million | ILA20.07 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ILA3.01 Million | ILA3.06 Million | ILA4.64 Million | ILA5.00 Million | ILA14.75 Million |
| Net Receivables | ILA74.02K | — | — | ILA47.00K | ILA48.00K |
| Inventory | — | — | — | ILA-39.00K | ILA-48.00K |
| Property, Plant & Equipment | — | — | — | ILA126.00K | ILA185.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ILA3.92 Million | ILA3.68 Million | ILA3.75 Million | ILA4.81 Million | ILA5.87 Million |
| Total Current Liabilities | ILA2.73 Million | ILA2.05 Million | ILA2.02 Million | ILA2.50 Million | ILA2.73 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | ILA-5.46 Million | ILA-4.72 Million | ILA-4.24 Million | ILA-2.92 Million | ILA-4.27 Million |
| Total Stockholder Equity | ILA5.59 Million | ILA5.44 Million | ILA6.24 Million | ILA4.47 Million | ILA14.38 Million |
| Retained Earnings | ILA-176.23 Million | ILA-166.36 Million | ILA-158.48 Million | ILA-150.85 Million | ILA-140.67 Million |
Can Fite Biopharma Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Can Fite Biopharma Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ILA-9.69 Million | ILA-7.64 Million | ILA-8.44 Million | ILA-10.80 Million | ILA-9.86 Million |
| Capital Expenditures | ILA2.17K | ILA5.00K | ILA2.00K | ILA9.00K | ILA11.00K |
| Free Cash Flow | ILA-9.69 Million | ILA-7.64 Million | ILA-8.44 Million | ILA-10.81 Million | ILA-9.87 Million |
| Investing Cash Flow | ILA-2.16K | ILA1.50 Million | ILA498.00K | ILA9.50 Million | ILA-14.51 Million |
| Financing Cash Flow | ILA10.44 Million | ILA6.71 Million | ILA9.14 Million | ILA6.53 Million | ILA20.46 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ILA340.00K | ILA362.00K | ILA261.00K | ILA263.00K | ILA466.00K |
| Depreciation | ILA25.98K | ILA7.00K | ILA15.00K | ILA14.00K | ILA14.00K |
| Change in Cash | ILA11.82K | ILA547.00K | ILA1.30 Million | ILA-1.41 Million | ILA-3.88 Million |
Can Fite Biopharma Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Can Fite Biopharma Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 28, 2025 | — | — | — |
| Apr 03, 2025 | — | — | — |
| Dec 31, 2024 | — | 0.00 | — |
| Sep 30, 2024 | — | 0.00 | — |
| Jun 30, 2024 | — | 0.00 | — |
| Mar 31, 2024 | — | 0.00 | — |
| Mar 28, 2024 | -110.01 | -0.97 | -11241.24% |
| Nov 30, 2023 | 0.00 | -1.64 | +100.00% |